NO20025630L - Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose - Google Patents

Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose

Info

Publication number
NO20025630L
NO20025630L NO20025630A NO20025630A NO20025630L NO 20025630 L NO20025630 L NO 20025630L NO 20025630 A NO20025630 A NO 20025630A NO 20025630 A NO20025630 A NO 20025630A NO 20025630 L NO20025630 L NO 20025630L
Authority
NO
Norway
Prior art keywords
dimethoxyphenyl
dopamine
dementia
prodrug
fluorophenyl
Prior art date
Application number
NO20025630A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025630D0 (no
Inventor
Richard Sheyer
Stephen M Sorensen
Janice Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20025630D0 publication Critical patent/NO20025630D0/no
Publication of NO20025630L publication Critical patent/NO20025630L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
NO20025630A 2000-05-25 2002-11-22 Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose NO20025630L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (2)

Publication Number Publication Date
NO20025630D0 NO20025630D0 (no) 2002-11-22
NO20025630L true NO20025630L (no) 2003-01-24

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025630A NO20025630L (no) 2000-05-25 2002-11-22 Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose

Country Status (20)

Country Link
US (3) US20020099076A1 (de)
EP (1) EP1289527B1 (de)
JP (1) JP2003535058A (de)
KR (1) KR100784655B1 (de)
CN (1) CN1436078A (de)
AR (1) AR029666A1 (de)
AT (1) ATE390134T1 (de)
AU (2) AU2001264842B2 (de)
BR (1) BR0111102A (de)
CA (1) CA2410554C (de)
DE (1) DE60133385T2 (de)
DK (1) DK1289527T3 (de)
ES (1) ES2300333T3 (de)
IL (1) IL152908A0 (de)
MX (1) MXPA02011511A (de)
NO (1) NO20025630L (de)
NZ (1) NZ522659A (de)
PT (1) PT1289527E (de)
TW (1) TWI299001B (de)
WO (1) WO2001089498A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1534391E (pt) 2002-07-19 2007-05-31 Biovitrum Ab Novos derivados e piperazinilo-pirazinona para o tratamento de desordens relacionadas com o receptor 5-ht
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017172757A1 (en) * 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4912117A (en) 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US4783471A (en) 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
US5106855A (en) 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US6004980A (en) 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
CA2083698C (en) 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
WO1999020315A1 (en) * 1997-10-23 1999-04-29 The Research Foundation Of State University Of New York Methods of screening potential atypical antipsychotic drugs
KR100682799B1 (ko) * 1998-08-28 2007-02-15 아벤티스 파마슈티칼스 인크. Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물
CA2347469C (en) * 1998-10-14 2006-02-28 Aventis Pharmaceuticals Inc. Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
NZ522659A (en) 2004-06-25
KR100784655B1 (ko) 2007-12-12
EP1289527A2 (de) 2003-03-12
US20020099076A1 (en) 2002-07-25
WO2001089498A2 (en) 2001-11-29
BR0111102A (pt) 2003-03-11
CA2410554C (en) 2009-02-03
TWI299001B (en) 2008-07-21
PT1289527E (pt) 2008-05-13
ES2300333T3 (es) 2008-06-16
AU6484201A (en) 2001-12-03
DE60133385T2 (de) 2009-04-23
EP1289527B1 (de) 2008-03-26
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
US20040204457A1 (en) 2004-10-14
DK1289527T3 (da) 2008-07-14
DE60133385D1 (de) 2008-05-08
US20030036553A1 (en) 2003-02-20
IL152908A0 (en) 2003-06-24
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13
JP2003535058A (ja) 2003-11-25
KR20030034078A (ko) 2003-05-01
MXPA02011511A (es) 2003-04-25
WO2001089498A3 (en) 2002-05-10
PL359176A1 (en) 2004-08-23
US7132433B2 (en) 2006-11-07
NO20025630D0 (no) 2002-11-22
AR029666A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
NO20015112L (no) Anvendelse av glykosylceramidsynteseinhibitorer ved terapi
LU91888I2 (fr) L'apixaban et ses sels pharmaceutiquement acceptables dans l'une quelconque des formes bénéficiant de la protection du brevet initial
GB0101577D0 (en) Compounds
NO20022585D0 (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av CNS-forstyrrelser
NO20025630D0 (no) Anvendelse av (+)-alfa-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol eller dets prodrug ved behandling av symptomer pådemens og dopaminindusert psykose
AU2001272852A1 (en) Composition for the treatment of migraine
NO20024808L (no) FremgangsmÕte ved syntesen av perindopril og farmasöytisk akseptable salter derav
DK1296705T3 (da) Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
AU2003260744A1 (en) 1, 4- substituted piperidine derivatives and use thereof as base-inhibitors in treatment of alzheimer's disease
AU2002314624A1 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
NO20032340L (no) Substituerte aminofuran-2-yl-eddiksyre- og aminotien-2-yl- eddiksyrederivater og deres anvendelse for behandling av migrene og henholdsvissmerte
DK0888114T3 (da) Anvendelse af (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-flourphenyl)-ethyl]-4-piperidinmethanol til behandling af depressive lidelser og bipolare lidelser
NO20043029L (no) Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer
GB2382011B (en) Secure and mediated access for e-services
ITMI20011032A0 (it) Macchina foratrice e fresatrice particolarmente studiata per l'applicazione di ferramenta ed elementi di mobili
NO20005037L (no) Paroksetinmaleat
NO20011805L (no) Estere av (+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol og deres anvendelse somprodrugs for 5HT2A reseptorantagonist MDL 110,907
MXPA03006534A (es) Metodo para obtener (3-ciano-1h-indol-7-il)-(4(4- fluorfenetil)-piperazin-1-il)-metanona y sus sales.
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
DK1239861T3 (da) Kombinationaf cyamemazin og et atypisk neuroleptikum
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
ITBO20000540A0 (it) Macchina per la lavorazione di pannelli di legno o similari

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application